Recent News

  • Avivagen enters into Partnership with CSA to Sell and Distribute OxC-beta™ Livestock in the United States

    Ottawa, ON /GlobeNewswire/ February 20, 2019 / – Avivagen Inc. (TSXV:VIV) (“Avivagen”) is pleased to announce that it has signed a partnership with CSA Animal Nutrition providing for the sales and distribution ofOxC-beta™Livestock (“OxC-beta”)by CSA in the United States.  Under the terms of the agreement, CSA will coordinate commercial scale validation research with potential customers …Read More

  • Avivagen Inc. Announces Results for Fiscal Year Ending October 31, 2018

    Ottawa, ON /GlobeNewswire/ January 31,  2019 / – Avivagen Inc. (TSXV:VIV) (“Avivagen”) reported its audited financial results for the year ended October 31, 2018. Unless otherwise noted, all figures are in Canadian currency. The Corporation’s audited year end Financial Statements and its Management’s Discussion and Analysis for the year ended October 31, 2018 have been …Read More

  • Avivagen Announces TSX Venture Exchange Approval for Extension of Warrants

    Ottawa, ON /GlobeNewswire/ January 18, 2019 – THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences innovation company with a series of patent protected products that support …Read More

  • Avivagen Announces CEO Letter to Shareholders

    Avivagen’s Chairman and interim CEO, Kym Anthony, updates shareholders on progress made in the Livestock, Companion Animal and Human Health markets.

  • Avivagen Announces Proposed Extension of Warrants

    Ottawa, ON /GlobeNewswire/ December 20, 2018 / – Avivagen Inc. (TSXV:VIV) (“Avivagen” or “Corporation”), a world leader in natural alternatives to antibiotics with its OxC-beta™ technology, today announced that it will be requesting approval from the TSX Venture Exchange for the extension of the expiration date of warrants exercisable to purchase 1,163,738 common shares at …Read More

View All News Releases

Media Coverage

  • VICTAM Asia

    Avivagen CEO Interviewed at VICTAM Asia 2018 Conference

    Avivagen recently debuted at the VICTAM ASIA 2018 Conference in Bangkok, Thailand.

  • CEO Kym Anthony Interviewed by Uptick

    CEO Kym Anthony was interviewed by the penny stock news and trends podcast, Uptick Newswire.

    I think if people keep their eyes on the size of the prize, [they’ll see] the livestock market is in the billions of dollars; our share of that would be in the hundreds of millions if we roll out successfully. The human market is untouched. The companion animal market is also big. We’ve spent years proving it works; everyone agrees it works. Now is the time to roll it out commercially.

  • CTV: Growing resistance to antibiotics fuels market for alternative solutions

    CTV NEWS, TORONTO – A hundred years ago, a small wound could result in death if an infection spread. That could become reality again as the world threatens to return to a pre-antibiotic era due to antibiotic resistance.

    Some have pointed to the widespread use of antibiotics in livestock feed as a culprit, resulting in urgent calls to quell their use and find alternatives.

View All Media Coverage